<DOC>
	<DOCNO>NCT01648192</DOCNO>
	<brief_summary>This study first study losmapimod Japanese subject . This study single-center , single blind , phase I two part study characterize safety , tolerability , pharmacokinetic pharmacodynamic profile healthy Japanese volunteer ( male female non-childbearing potential ) . Part1 single dose , randomize , three-period , placebo-controlled dose escalation part . Each subject participate 3 dose session , receive , separate day , three four treatment losmapimod 2.5 , 7.5 20 mg , match placebo fast state overnight fast ( least 10 hour ) . The design incorporate sufficient washout treatment ( least 7 day previous administration ) , efficient design study objective . Part 2 fix dose placebo-controlled part . Each subject participate one dose session , receive losmapimod 7.5 mg match placebo twice daily fast state 14 day . Only subject blind sequence dose study . The study include placebo treatment allow valid evaluation adverse event attributable treatment versus independent treatment . Approximately 18 subject part receive treatment losmapimod and/or placebo design . The primary objective study characterize safety tolerability single dose repeat dos losmapimod healthy Japanese subject . Serial pharmacokinetic sample collect safety assessment perform follow dose .</brief_summary>
	<brief_title>Phase I Study GW856553 ( Losmapimod )</brief_title>
	<detailed_description />
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<criteria>Healthy determine responsible experienced physician , base medical evaluation include medical history , physical examination , laboratory test cardiac monitoring . A subject clinical abnormality laboratory parameter outside reference range population study may include Investigator GSK Medical Monitor agree find unlikely introduce additional risk factor interfere study procedure . Male female 20 55 year age inclusive , time signing informed consent . A female subject eligible participate : Nonchildbearing potential define premenopausal female . Male subject female partner childbearing potential must agree use one contraception method . This criterion must follow time first dose study medication followup visit . Body weight &gt; = 45 kg BMI within range 18.5 29.0 kg/m2 ( inclusive ) . Japanese define born Japan , four ethnic Japanese grandparent , hold Japanese passport identity paper able speak Japanese . Japanese subject must live outside Japan 10 year . ALT , alkaline phosphatase bilirubin &lt; = 1.5xULN ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . Single QTc , QTcB QTcF &lt; 450 msec . A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . A positive prestudy drug/alcohol screen . A positive test HIV antibody . History regular alcohol consumption within 6 month study define : average weekly intake great 21 unit men 14 woman average daily intake great 3 unit . One unit equivalent 285 mL glass full strength beer 425 mL schooner light beer 1 ( 30 mL ) measure spirit 1 glass ( 100 mL ) wine ( NHMRC Guidelines [ NHMRC , 2009 ] ) The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . Exposure four new chemical entity within 12 month prior first dose day . Unable refrain use prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St John 's Wort ) within 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( whichever longer ) prior first dose study medication , unless opinion Investigator GSK Medical Monitor medication interfere study procedure compromise subject safety . History sensitivity study medication , component thereof history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation . Where participation study would result donation blood blood product excess 500 mL within 56 day period . Pregnant female determine positive urine hCG test screen prior dosing . Lactating female . Unwillingness inability follow procedure outline protocol . Subject mentally legally incapacitate . History regular use tobacco nicotinecontaining product within 6 month prior screen .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>